Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

被引：0
|
作者：
Hanzel, J. [1 ]
Sever, N. [1 ]
Ferkolj, I. [1 ]
Stabuc, B. [1 ]
Smrekar, N. [1 ]
Kozelj, M. [1 ]
Novak, G. [1 ]
Gils, A. [2 ]
Drobne, D. [1 ]
机构：
[1] Univ Med Ctr Ljubljana, Dept Gastroenterol, Ljubljana, Slovenia
[2] Katholieke Univ Leuven, Lab Pharmaceut Biol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P603
引用
收藏
页码：S414 / S414
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of vedolizumab withdrawal in inflammatory bowel disease for patients in histological remission
    Blad, William
    Whitley, Lisa
    Harrow, Paul
    [J]. GUT, 2023, 72 (SUPPL_2) : A87 - A88
  • [32] Fecal Calprotectin Does Not Predict Endoscopic Remission in Inflammatory Bowel Disease
    Falvey, James D.
    Gearry, Richard B.
    Day, Andrew S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : E80 - E81
  • [33] LOW INFLIXIMAB TROUGH LEVELS AT WEEK 6 AND 14 IN AN ASIAN INFLAMMATORY BOWEL DISEASE COHORT ARE NOT ASSOCIATED WITH POORER CLINICAL OUTCOME
    Lim, Chong Teik
    Koh, Samantha J.
    Tay, Shu Wen
    Salazar, Ennaliza
    Chan, Pak Wo
    Tan, Malcolm
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S1095 - S1096
  • [34] Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab
    Jeffrey, A. W.
    Picardo, S.
    So, K.
    Menon, S.
    Venugopal, K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 119 - 119
  • [35] INFLIXIMAB PEAK AND 1-WEEK SERUM LEVEL ESTIMATES PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Hellstrom, Per M.
    Saaed, Hiwa
    Hernandez, Armando
    Touny, Aya A.
    Webb, Dominic-Luc
    Fogdell-Hahn, Anna
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S804 - S805
  • [36] Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
    O'Connell, J.
    McDonagh, P.
    Hazel, K.
    Fiona, J.
    Dunne, C.
    Farrell, R.
    Harewood, G.
    Hartery, K.
    Kelly, O.
    MacCarthy, F.
    McKiernan, S.
    Murray, F.
    O'Morain, C.
    Aoibhlinn, O.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S473 - S473
  • [37] Fecal Calprotectin Does Not Predict Endoscopic Remission in Inflammatory Bowel Disease Reply
    D'Haens, Geert
    Vermeire, Severine
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : E81 - E81
  • [38] Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease
    Chaparro, M.
    Sierra-Ausin, M.
    Mesonero, F.
    Maroto, N.
    Fernandez de Castro, C.
    Garcia-Sanchez, V.
    Lucendo, A. J.
    Busquets, D.
    Barreiro-de Acosta, M.
    Marin-Jimenez, I.
    Beltran, B.
    Ruiz Belmonte, L.
    Bermejo, F.
    Minguez, M.
    Pajares, R.
    Pineda, J. R.
    Sicilia, B.
    Martin-Rodriguez, D.
    Gutierrez, A.
    Rubio, S.
    Garcia Tercero, I.
    Piqueras, M.
    Ginard, D.
    Jucha, B.
    Munoz Villafranca, C.
    Martin-Arranz, M. D.
    Marti Romero, L.
    Fernandez Bonilla, E. M.
    Echarri, A.
    Forcelledo, J. F.
    Donday, M. G.
    Ramas, M.
    Gisbert, J. P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S416 - S417
  • [39] Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease
    Courbette, Olivier
    Aupiais, Camille
    Viala, Jerome
    Hugot, Jean-Pierre
    Roblin, Xavier
    Candon, Sophie
    Louveau, Baptiste
    Chatenoud, Lucienne
    Martinez-Vinson, Christine
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 310 - 317
  • [40] In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab
    Loly, Jean-Philippe
    Vieujean, Sophie
    Reenaers, Catherine
    Van Kemseke, Catherine
    Seidel, Laurence
    Louis, Edouard
    Somja, Joan
    [J]. INFLAMMATORY BOWEL DISEASES, 2024, 30 (02) : 240 - 246
12345